



300 NW 70th Avenue, Suite 102 • Plantation, Florida 33317
(954) 723-0057 Phone • (954) 723-0353 Fax
email: info@naceonline.com

**Clinical Updates for
Nurse Practitioners and
Physician Assistants: 2012/2013**



**November 3, 2012
Pittsburgh Marriott City Center
Pittsburgh, PA**

Course Directors
Deborah Paschal, CRNP
Gregg Sherman, MD

Activity Director
Michelle Frisch, MPH, CCMEP

Program Evaluation
December 4, 2012

In November 2012, the National Association for Continuing Education (NACE) sponsored a CE activity, *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Pittsburgh, PA.

This educational activity was designed to provide nurse practitioners and physician assistants the opportunity to learn about Osteoporosis, Psoriasis, Inflammatory Bowel Disease, Diabetes, and Atrial Fibrillation.

In planning this CE activity, NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Sixty eight healthcare practitioners registered to attend *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Pittsburgh, PA. Thirty eight healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Thirty eight completed forms were received. The data collected is displayed in this report.

CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.


Physician assistants may receive a maximum of 6 hours of Category 1 credit for completing this program.

This program is approved for 6.0 contact hours of continuing education (which includes 4.75 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1209349

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.


What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	0	0.00	0.00
DO	0	0.00	0.00
NP	25	65.79	65.79
PA	13	34.21	34.21
RN	0	0.00	0.00
Other	0	0.00	0.00
Total Valid	38	100.00	100.00




What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	19	50.00	51.35
Endocrinology	2	5.26	5.41
Rheumatology	0	0.00	0.00
Pulmonology	0	0.00	0.00
Cardiology	4	10.53	10.81
Gastroenterology	0	0.00	0.00
OB/GYN	3	7.89	8.11
Other	9	23.68	24.32
Total Valid	37	97.37	100.00
Total Missing	1	2.63	
Total	38	100.00	




Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and nonpharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; and use currently available laboratory tests to maximize benefit while minimizing toxicity:

Label	Frequency	Percent	Valid Percent
Yes	32	84.21	86.49
Somewhat	5	13.16	13.51
Not at all	0	0.00	0.00
Total Valid	37	97.37	100.00
Total Missing	1	2.63	
Total	38	100.00	




Upon completion of this activity, I can now - Explain the current pathophysiologic mechanisms associated with the development of psoriatic disease; discuss the impact of psoriatic disease including its effects on mood, cardiovascular risk, quality of life, and other co-morbid conditions; recognize the percent of body surface area that categorizes a patient for topical or systemic therapy; and implement appropriate treatment plans for patients who are candidates for topical and/or systemic therapy:

Label	Frequency	Percent	Valid Percent
Yes	31	81.58	81.58
Somewhat	7	18.42	18.42
Not at all	0	0.00	0.00
Total Valid	38	100.00	100.00




Upon completion of this activity, I can now - Identify appropriate candidates for BMD testing incorporating the FRAX 10-year fracture risk into treatment decisions; initiate pharmacologic therapy for patients who meet NOF guideline recommendations for pharmacologic management; implement education for dietary and supplemental calcium and vitamin D and exercises to prevent osteoporosis and related fractures; and recognize and overcome barriers to adherence and effectiveness of osteoporosis therapy:

Label	Frequency	Percent	Valid Percent
Yes	34	89.47	91.89
Somewhat	3	7.89	8.11
Not at all	0	0.00	0.00
Total Valid	37	97.37	100.00
Total Missing	1	2.63	
Total	38	100.00	




Upon completion of this activity, I can now - Discuss the role of the incretin system in the pathophysiology of type 2 diabetes (T2DM); define the role of GLP-1 receptor agonist therapy in the treatment algorithm for T2DM; identify the features, benefits, and limitations of individual GLP-1 agonists; discuss the appropriate selection of GLP-1 receptor agonist therapy according to the glycemic disturbance most in need of correction:

Label	Frequency	Percent	Valid Percent
Yes	15	39.47	42.86
Somewhat	14	36.84	40.00
Not at all	6	15.79	17.14
Total Valid	35	92.11	100.00
Total Missing	3	7.89	
Total	38	100.00	




Upon completion of this activity, I can now - Use of the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); recognize the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify safe and effective use of new and emerging antithrombotic therapy for AF patients related to the risk stratification for stroke; and identify relevant patient characteristics to guide the selection and monitoring of antithrombotic therapy in patients with atrial fibrillation:

Label	Frequency	Percent	Valid Percent
Yes	30	78.95	90.91
Somewhat	2	5.26	6.06
Not at all	1	2.63	3.03
Total Valid	33	86.84	100.00
Total Missing	5	13.16	
Total	38	100.00	




Overall, I would rate this activity as:

Label	Frequency	Percent	Valid Percent
Excellent	19	50.00	50.00
Very Good	18	47.37	47.37
Good	1	2.63	2.63
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	38	100.00	100.00




Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid Percent
Strongly Agree	16	42.11	42.11
Agree	21	55.26	55.26
Neutral	1	2.63	2.63
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	38	100.00	100.00




Overall, this activity was effective in improving my knowledge in the content areas presented:

Label	Frequency	Percent	Valid Percent
Strongly Agree	17	44.74	44.74
Agree	21	55.26	55.26
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	38	100.00	100.00




As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid Percent
Strongly Agree	16	42.11	42.11
Agree	19	50.00	50.00
Neutral	3	7.89	7.89
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	38	100.00	100.00




How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	19	50.00	51.35
Somewhat likely	13	34.21	35.14
Unlikely	0	0.00	0.00
Not applicable	5	13.16	13.51
Total Valid	37	97.37	100.00
Total Missing	1	2.63	
Total	38	100.00	




When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	24	63.16	64.86
1-3 months	5	13.16	13.51
4-6 months	2	5.26	5.41
Not applicable	6	15.79	16.22
Total Valid	37	97.37	100.00
Total Missing	1	2.63	
Total	38	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Gerald W. Dryden, MD (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	28	73.68	75.68
Very Good	8	21.05	21.62
Good	0	0.00	0.00
Fair	1	2.63	2.70
Unsatisfactory	0	0.00	0.00
Total Valid	37	97.37	100.00
Total Missing	1	2.63	
Total	38	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Brad P. Glick, DO (Psoriasis):

Label	Frequency	Percent	Valid Percent
Excellent	25	65.79	65.79
Very Good	10	26.32	26.32
Good	2	5.26	5.26
Fair	1	2.63	2.63
Unsatisfactory	0	0.00	0.00
Total Valid	38	100.00	100.00




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Sandra Kesner, CNP, MSN (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	21	55.26	58.33
Very Good	9	23.68	25.00
Good	5	13.16	13.89
Fair	1	2.63	2.78
Unsatisfactory	0	0.00	0.00
Total Valid	36	94.74	100.00
Total Missing	2	5.26	
Total	38	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Brenda Blyler, MSN, CRNP (Diab):

Label	Frequency	Percent	Valid Percent
Excellent	7	18.42	20.00
Very Good	6	15.79	17.14
Good	11	28.95	31.43
Fair	5	13.16	14.29
Unsatisfactory	6	15.79	17.14
Total Valid	35	92.11	100.00
Total Missing	3	7.89	
Total	38	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Kathleen Higgens, CRNP (AFib):

Label	Frequency	Percent	Valid Percent
Excellent	26	68.42	78.79
Very Good	3	7.89	9.09
Good	4	10.53	12.12
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	33	86.84	100.00
Total Missing	5	13.16	
Total	38	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Gerald W. Dryden, MD (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	32	84.21	88.89
Very Good	3	7.89	8.33
Good	0	0.00	0.00
Fair	1	2.63	2.78
Unsatisfactory	0	0.00	0.00
Total Valid	36	94.74	100.00
Total Missing	2	5.26	
Total	38	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Brad P. Glick, DO (Psoriasis):

Label	Frequency	Percent	Valid Percent
Excellent	31	81.58	83.78
Very Good	5	13.16	13.51
Good	0	0.00	0.00
Fair	1	2.63	2.70
Unsatisfactory	0	0.00	0.00
Total Valid	37	97.37	100.00
Total Missing	1	2.63	
Total	38	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Sandra Kesner, CNP, MSN (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	29	76.32	78.38
Very Good	5	13.16	13.51
Good	2	5.26	5.41
Fair	1	2.63	2.70
Unsatisfactory	0	0.00	0.00
Total Valid	37	97.37	100.00
Total Missing	1	2.63	
Total	38	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Brenda Blyler, MSN, CRNP (Diab):

Label	Frequency	Percent	Valid Percent
Excellent	19	50.00	54.29
Very Good	8	21.05	22.86
Good	2	5.26	5.71
Fair	3	7.89	8.57
Unsatisfactory	3	7.89	8.57
Total Valid	35	92.11	100.00
Total Missing	3	7.89	
Total	38	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Kathleen Higgens, CRNP (AFib):

Label	Frequency	Percent	Valid Percent
Excellent	28	73.68	84.85
Very Good	3	7.89	9.09
Good	2	5.26	6.06
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	33	86.84	100.00
Total Missing	5	13.16	
Total	38	100.00	




Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent	Valid Percent
Topics covered	20	52.63	52.63
Location/ease of access	20	52.63	52.63
Faculty	6	15.79	15.79
Earn CME credits	30	78.95	78.95
Total Valid	38	100.00	100.00



Future CE activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid Percent
Strongly agree	11	28.95	30.56
Agree	16	42.11	44.44
Neutral	9	23.68	25.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	36	94.74	100.00
Total Missing	2	5.26	
Total	38	100.00	



What is your professional degree?

Comment

What is your specialty?

Comment
Allergy/Asthma
Geriatrics
School Health
FNP
General Surgery
College Health
Psychiatry
Psychiatry
Osteoporosis

As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment
New medications, updated guidelines
Evaluate for osteoporosis
Medications which can be used to treat the various conditions and a better understanding of the physiology
I practice outside of primary care, will not use regularly but great information to have
Recognizing symptoms diff IBD, use of FRAX, systemic Tx of psoriasis
Use of CHADS-helpful
Initial work-up of inflammatory bowel disease and psoriasis; improved comfort with use of GLP-1 in diabetics
Use new anti-coagulants; use of new medications in diabetes control; use of systemic therapy in both psoriasis and IBD
Evaluation and treatment of osteoporosis-how to determine which med should be use for which pt. Management of psoriasis was excellent
CHAD score, anticoagulation, ACCP AT9 guidelines
Referencing FRAX; referring time to rheumatologist
IBS-utilize questionnaire for IBS check symptoms and check eye symptoms; Dexa scan when to order and FRAX scores-great resource to use with patients
Updates in pharmacology and treatments
New guidelines to manage A-fib, diabetes, and psoriasis
Tx options for IBD as a primary care provider; confidence in using CHADS2 scoring for stratify anticoag; recognizing and deciding on tx options for psoriasis on PA
Use of combination therapy for psoriasis/psarthritis; use of biologicals for both IBD and psoriasis/psarthritis; risk for fx in osteo patients-identifying and referral
Systemic tx for psoriasis and arthritis=systemic sx's; monitor vs treat low bone density vs osteoporosis-check FRAX
Confidence increased
Understand new guidelines
New treatment plans for discussed topics
I have learned numerous treatments for diabetes
Power points good-good handouts
I feel more comfortable with newer therapies-such as with diabetes-victosa; and atrial fibrillation-Pradaxa; that I didn't feel as comfortable with previously
Treatment options for IBD. Using Vitamin D for psoriasis
Difference of IBD vs BS; use of the CHADS; use of GLP-1 more quickly with Tx; looking further in patients with psoriasis
The osteoporosis lecture most directly effects my practice. Great algorithm for Rx the correct medication and determining drug holidays
Use of FRAX tool-how to consider/recommend DEXA; options for psoriasis; testing for IBD
Will use CHADS score even though I don't care or tx ARG-I do HF

What topics would you like to see offered as CE activities in the future?

Comment
Renal Insufficiency, chronic sinusitis, hypotension
Any OB or GYN topics; diabetes
HTN, asthma
COPD, hypothyroidism, pharm/classes
Immunization update and challenges; use of vitamins/supplements from OTC and potential toxicities-B12, folate, Vitamin D
Pulmonary HTN
More related to anything women's health
Women's health, peds
Current treatment and recommendation for back pain; hypertension
Cyclic vomiting; sickle cell anemia; breast cancer; hereditary argoedema; gastric bypass surgery
CAD; family practice guidelines and new treatment options
Dermatology; infectious Dz
ADHD management; weight loss strategies; renal disease
Thyroid mgmt, COPD, new HTN agents, anemia, new psych agents and uses
Surgery
Orthopedics; neuro
Psych for primary care
Hypothyroidism
Treatment of mood and anxiety disorders in primary care
COPD, fracture care, renal topics
ENT
Please use more trade names along with generic names; speakers need to be more clear when reviewing answers to case study questions
CHF, kidney failure-chronic and acute; immunizations; COPD
Pediatric issues
Pediatrics; antibiotic tx
OB GYN; dermatology
Afib treatment in cath/open heart patients

Additional comments:

Comment
Thank you
Excellent program
Thanks so much-very interesting program-great speakers
DMII talk could have been better
I liked the interactive format
Good CE program
All good topics
Very nice conference. This is my first NACE event and I was very pleased
Dr. Glick was a little brash with fielding question on vaccination "You got that?"
Pharmacy credits are key
Thank you
Nice place. Great cost
All talks were very good. Diabetes speaker needed more preparation.
Pain management; arrhythmias
Thank you for offering a free course especially with pharmacology credit. The topics were relevant and the interactive format was engaging.
Enjoyed IBD and AFB speakers
Overall a nice conference
Speakers assume we know a lot about their subjects. Should start with a little more intro and history in all topics. Kesner was an especially good speaker.
I thought the conference was very effective and beneficial especially with being free of cost
Thank you. Enjoyed all. Especially the price
Great CME course
Thank you for hosting a CME at no cost

Item Statistics:

	Title	Specialty	Learning Objectives1	Learning Objectives2	Learning Objectives3	Learning Objectives4	Learning Objectives5
Mean	3.34	3.68	1.14	1.18	1.08	1.74	1.12
Variance	0.23	9.73	0.12	0.15	0.08	0.55	0.17
Standard Deviation	0.48	3.12	0.35	0.39	0.28	0.74	0.42
Standard Error	0.08	0.51	0.06	0.06	0.05	0.13	0.07
Minimum	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	4.00	8.00	2.00	2.00	2.00	3.00	3.00
Median	3.00	1.00	1.00	1.00	1.00	2.00	1.00
Range	1.00	7.00	1.00	1.00	1.00	2.00	2.00

	Overall Activity	Enhancing My Confidence	Improving My Knowledge	Patient Care	Make Changes	Implement New Strategies	Gerald W Dryden MD {IBD}
Mean	1.53	1.61	1.55	1.66	1.76	1.73	4.70
Variance	0.31	0.30	0.25	0.39	1.02	1.31	0.38
Standard Deviation	0.56	0.55	0.50	0.63	1.01	1.15	0.62
Standard Error	0.09	0.09	0.08	0.10	0.17	0.19	0.10
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	2.00
Maximum	3.00	3.00	2.00	3.00	4.00	4.00	5.00
Median	1.50	2.00	2.00	2.00	1.00	1.00	5.00
Range	2.00	2.00	1.00	2.00	3.00	3.00	3.00

	Brad P Glick DO {Psoriasis}	Sandra Kesner CNP {Osteo}	Brenda Blyler MSN {Diab}	Kathleen Higgins CRNP {AFib}	Gerald W Dryden MD {IBD} Bias	Brad P Glick DO {Psoriasis} Bias	Sandra Kesner CNP {Osteo} Bias
Mean	4.55	4.39	3.09	4.67	4.83	4.78	4.68
Variance	0.52	0.70	1.85	0.48	0.31	0.34	0.50
Standard Deviation	0.72	0.84	1.36	0.69	0.56	0.58	0.71
Standard Error	0.12	0.14	0.23	0.12	0.09	0.10	0.12
Minimum	2.00	2.00	1.00	3.00	2.00	2.00	2.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	3.00	5.00	5.00	5.00	5.00
Range	3.00	3.00	4.00	2.00	3.00	3.00	3.00

	Brenda Blyler MSN {Diab} Bias	Kathleen Higgins CRNP {AFib} Bias	Reasons for Participating	Future CE Activities
Mean	4.06	4.79	-	1.94
Variance	1.76	0.30	-	0.57
Standard Deviation	1.33	0.55	-	0.75
Standard Error	0.22	0.09	-	0.13
Minimum	1.00	3.00	-	1.00
Maximum	5.00	5.00	-	3.00
Median	5.00	5.00	-	2.00
Range	4.00	2.00	-	2.00